Advertisement
YOU ARE HERE: LAT HomeCollectionsRezulin
IN THE NEWS

Rezulin

FEATURED ARTICLES
CALIFORNIA | LOCAL
December 29, 1998
Two Times articles (Dec. 6, 7) and an editorial (Dec. 13) contain several half-truths and misstatements regarding Warner-Lambert's therapy for Type 2 diabetes, Rezulin, and the company's interactions with the U.S. Food and Drug Administration and the National Institutes of Health. Rezulin offers unique and substantial benefits for the treatment of Type 2 diabetes and has been used safely in more than 1 million patients. To suggest that the drug is unsafe is a disservice to Type 2 diabetes patients--and simply wrong.
ARTICLES BY DATE
BUSINESS
October 6, 2006 | From Bloomberg News
Pfizer Inc. must defend a lawsuit in which people claim its diabetes drug Rezulin damaged their livers. A federal appeals court in New York reinstated a case dismissed last year in a lower court. The appeals court said New York-based Pfizer wasn't shielded from the suit by state law in Michigan, as the lower-court judge had found. Plaintiffs in the case live in Michigan. Pfizer did not immediately comment.
Advertisement
CALIFORNIA | LOCAL
March 27, 2000
Finally, the FDA has come to its senses and withdrawn the diabetes drug Rezulin (March 22). As a diabetic living with this condition for 25 years, let those at Warner-Lambert know it is enough of a challenge dealing with this disease. The responsibility of numerous daily injections, blood testing, maintaining a restricted diet, avoiding diabetic complications and coping with debilitating high and low blood-sugar episodes are more than enough. We should not have to assume the responsibility of checking that the drugs we are prescribed are "safe."
CALIFORNIA | LOCAL
May 28, 2004 | Jean Guccione, Times Staff Writer
After just two days of deliberations, a Los Angeles jury unanimously rejected claims Thursday that the diabetes drug Rezulin -- taken off the market in March 2000 because of safety concerns -- contributed to the deaths or illness of three people. The oval, tan pill, which generated $2.1 billion in sales, was used by 2 million people and linked to 63 confirmed fatalities during the more than two years it was available to the public. Since then, the pill's manufacturer, Warner-Lambert Co.
CALIFORNIA | LOCAL
March 14, 2001
As a practicing physician, I appreciate your March 11 story, "Risk Was Known as FDA OKd Fatal Drug." When the diabetes drug Rezulin was still on the market, I was pushing for its withdrawal, or at least a "black box" warning to physicians. Since its inception in the early 1900s, the congressional mandate to the Food and Drug Administration has been to protect the public. In the 1990s, when Congress asked the FDA to speed approval for drugs that could potentially save lives in hopeless diseases such as AIDS and terminal cancer (fast-track approval)
NEWS
December 6, 1998
1996 June: The National Institutes of Health launches a $150-million experiment, testing whether Rezulin or another drug can prevent adult-onset diabetes. July 31: Warner-Lambert Co. applies to the Food and Drug Administration for approval of Rezulin as a prescription drug. Oct. 9: A veteran FDA medical officer recommends rejecting Rezulin, citing potential danger to the liver and heart as well as doubts about the drug's effectiveness. Nov.
BUSINESS
October 6, 2006 | From Bloomberg News
Pfizer Inc. must defend a lawsuit in which people claim its diabetes drug Rezulin damaged their livers. A federal appeals court in New York reinstated a case dismissed last year in a lower court. The appeals court said New York-based Pfizer wasn't shielded from the suit by state law in Michigan, as the lower-court judge had found. Plaintiffs in the case live in Michigan. Pfizer did not immediately comment.
CALIFORNIA | LOCAL
December 24, 1999
As a Type 2 diabetic who has benefited significantly from Rezulin, I find your coverage of the medication very troubling indeed (Dec. 15). Reviewing your extensive coverage over the last 14 months, it seems clear that The Times is taking a rather strong position advocating FDA withdrawal of this drug. Your sources are limited to those who support this view, with virtually no reference to the drug's benefits in curbing diabetes. Like many prescription drugs, Rezulin can have devastating side effects.
CALIFORNIA | LOCAL
October 25, 2000
"Key FDA Aide in Rezulin Case Resigns" (Oct. 18), on the resignation of Dr. Murray Lumpkin, did a major disservice to the Food and Drug Administration and, more important, Dr. Lumpkin. He resigned for personal reasons alone, and the FDA respects his right to privacy as a career, nonpolitical employee. The FDA's handling of Rezulin has been a matter of public record. The FDA convened three public advisory committee meetings and followed the committee's advice. All actions on this product were discussed and supported at the highest levels of the FDA. The American people have been well served by Lumpkin's dedication to the public health.
CALIFORNIA | LOCAL
March 25, 1999
On Friday the Food and Drug Administration is scheduled to hold a public hearing to decide whether to restrict or prohibit doctors from prescribing Rezulin, a diabetes drug the agency "associates" with at least 33 deaths involving liver damage over the last two years. The Times' own analysis shows that the toll could be much higher--that doctors and others have reported 155 deaths in which Rezulin was cited as a suspect drug.
BUSINESS
July 9, 2003 | From Bloomberg News
Pfizer Inc. must face a class-action suit in West Virginia over its Rezulin diabetes drug's role in destroying some patients' livers, a state appeals court ruled. The West Virginia Supreme Court reversed a lower court ruling denying 5,000 former Rezulin users the right to join together to sue the drug maker over the costs of monitoring their health in the future. Pfizer's shares fell 9 cents to $34.31 on the NYSE.
NATIONAL
September 13, 2002 | From Times Wire Reports
Pfizer Inc. won't have to face a nationwide class-action suit over its Rezulin diabetes drug that's been linked to liver problems, a federal judge ruled. U.S. District Judge Lewis A. Kaplan rejected a bid by plaintiffs to combine claims from more than 2 million former Rezulin users into a single case in federal court in New York. Kaplan said consumers' problems with the drug were too individualized to warrant treatment as a class.
NATIONAL
June 30, 2002 | DAVID WILLMAN, TIMES STAFF WRITER
Newly obtained internal documents show that Warner-Lambert Co. executives who promoted the diabetes pill Rezulin masked from federal regulators early indications of the drug's danger to the liver and later delayed sharing information about its lethal toxicity with family doctors. The newly acquired materials show that company management rebuffed employees who questioned liver-injury totals from clinical studies that excluded 38% of the cases.
NEWS
March 26, 2002 | From Times Wire Reports
Warner-Lambert Co. unit must pay $1.55 million in damages to the family of a man who died after taking its Rezulin diabetes drug for about a month, a jury ruled. State court jurors in Tulsa deliberated more than 10 hours before voting, 10-2, that Rezulin was responsible for Michael Wakefield's death. The 41-year-old salesman died of liver failure in 1999.
BUSINESS
February 6, 2002 | From Reuters
A Maryland jury on Tuesday found Warner-Lambert, which had supplied the prescription diabetes drug Rezulin before being bought by drug maker Pfizer Inc., not guilty in the death of Monica George, Pfizer said. Pfizer, which bought Warner-Lambert in June 2000, said it was pleased with the court's decision and will defend all remaining Rezulin suits. The case was heard in the Montgomery County Circuit Court in Rockville, Md. Pfizer had said Jan.
NEWS
January 23, 2002 | From Times Wire Reports
A Texas jury ordered drug maker Pfizer Inc. to pay $1.5 million in punitive damages in addition to an earlier $23.46-million award to the family of a woman who died after taking the diabetes drug Rezulin, a spokesman for Pfizer said. Pfizer spokesman Robert Fauteax restated the company's intention to appeal the verdict. In a release last week, Pfizer said the state court had limited its defense time, excluded relevant evidence and improperly admitted evidence.
CALIFORNIA | LOCAL
June 7, 2000
Re "The Rise and Fall of the Killer Drug Rezulin," June 4: The response of FDA officials regarding what they learned from this disaster falls far short. They talk about labeling and warnings but there are some other lessons they should have learned. 1. FDA officials should free themselves from the influence of the drug companies. Your article points out that Warner-Lambert had undue influence on many of the high officials in the FDA. 2. The FDA surely should be more concerned about people's health than with currying favor with Warner-Lambert.
NEWS
January 19, 2002 | From Bloomberg News
Pfizer Inc.'s Warner-Lambert Co. unit must pay $23.4 million in compensatory damages to the family of a woman who died after taking the company's Rezulin diabetes drug, a Texas jury decided Friday. Jurors in state court in Edinburg deliberated more than four hours before finding Rezulin was responsible for Beatrice Herrera's death. The 80-year-old woman died of liver failure after taking the diabetes drug for three months.
BUSINESS
January 18, 2002 | Bloomberg News
Pfizer Inc. said a California judge denied class-action status to a lawsuit claiming that advertising for the Rezulin diabetes drug misled consumers about its health risks. Los Angeles Superior Court Judge Ann Kough concluded there were not enough common claims among more than 200,000 Rezulin users in California to let them pursue the false-advertising suit as a class-action case, Pfizer said. Consumers across the country have filed suits contending that Rezulin caused fatal damage.
Los Angeles Times Articles
|